Abuse-Resistant Opioids: How Much Deterrence Is Enough For A Labeling Claim?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee will consider post-market study plans for King's Embeda and Purdue's reformulated OxyContin.